QGEN Competition Analysis

Qiagen N.V. Peer Comparison

Metric	Value	Ranking
Market Cap	$9.2 Billion	4/13	IQV $24.7B	NTRA $20.8B	ICLR $10.6B	QGEN $9.2B	MEDP $8.8B	GH $5.0B	SYNH $4.5B	SHC $3.6B	OLK $3.2B	NEOG $1.4B	NEO $201.8M	ACRS $132.1M	AKU $26.4M
Gross Margin	67%	1/13	QGEN 67%	NTRA 63%	GH 62%	OLK 61%	SHC 57%	NEOG 49%	NEO 45%	IQV 35%	MEDP 33%	ICLR 29%	SYNH 22%	AKU 14%	ACRS -1%
Profit Margin	17%	2/13	MEDP 22%	QGEN 17%	ICLR 13%	IQV 11%	SHC 4%	SYNH 0%	NEO -9%	NTRA -11%	AKU -52%	GH -55%	OLK -56%	ACRS -100%	NEOG -100%
EBITDA margin	36%	1/13	QGEN 36%	SHC 30%	IQV 26%	MEDP 23%	ICLR 18%	AKU 14%	SYNH 8%	NEO 2%	NTRA -10%	GH -49%	OLK -73%	ACRS -151%	NEOG -198%
Quarterly Revenue	$521.2 Million	5/13	IQV $4.0B	ICLR $2.0B	SYNH $1.4B	MEDP $536.6M	QGEN $521.2M	NTRA $476.1M	SHC $290.2M	NEOG $231.3M	GH $201.8M	AKU $184.8M	NEO $172.0M	OLK $28.6M	ACRS $9.2M
Quarterly Earnings	$88.3 Million	4/13	IQV $437.0M	ICLR $260.0M	MEDP $117.0M	QGEN $88.3M	SHC $12.3M	SYNH $793,000	NEO -$15.3M	OLK -$16.0M	NTRA -$53.8M	ACRS -$96.6M	AKU -$96.7M	GH -$111.0M	NEOG -$456.3M
Quarterly Free Cash Flow	$142.8 Million	3/13	ICLR $277.0M	MEDP $183.0M	QGEN $142.8M	NEOG $78.7M	NTRA $34.8M	AKU $5.7M	NEO -$1.8M	OLK -$8.2M	SHC -$10.2M	ACRS -$44.7M	SYNH -$51.6M	GH -$83.4M	IQV -$0
Trailing 4 Quarters Revenue	$2.0 Billion	5/13	IQV $15.4B	ICLR $8.3B	SYNH $5.4B	MEDP $2.1B	QGEN $2.0B	NTRA $1.7B	SHC $1.1B	NEOG $913.8M	AKU $743.7M	GH $739.0M	NEO $660.6M	OLK $171.4M	ACRS $18.7M
Trailing 4 Quarters Earnings	$83.6 Million	4/13	IQV $4.0B	ICLR $2.0B	SYNH $1.4B	MEDP $536.6M	QGEN $521.2M	NTRA $476.1M	SHC $290.2M	NEOG $231.3M	GH $201.8M	AKU $184.8M	NEO $172.0M	OLK $28.6M	ACRS $9.2M
Quarterly Earnings Growth	-10%	7/13	MEDP 49%	GH 41%	NTRA 31%	ICLR 0%	IQV -7%	NEO -7%	QGEN -10%	OLK -14%	SHC -68%	SYNH -99%	AKU -271%	ACRS -6376%	NEOG -12985%
Annual Earnings Growth	-75%	10/13	SHC 2031%	ICLR 61%	NTRA 53%	MEDP 39%	GH 2%	IQV 0%	NEO -13%	ACRS -48%	SYNH -67%	QGEN -75%	AKU -117%	OLK -1544%	NEOG -46707%
Quarterly Revenue Growth	2%	6/13	NTRA 53%	GH 30%	NEO 11%	MEDP 8%	OLK 4%	QGEN 2%	IQV 2%	NEOG 1%	SYNH 0%	ICLR 0%	AKU -4%	SHC -6%	ACRS -48%
Annual Revenue Growth	2%	6/13	NTRA 52%	ICLR 34%	GH 27%	NEO 8%	MEDP 7%	QGEN 2%	IQV 2%	SYNH 1%	NEOG 0%	SHC 0%	AKU -1%	OLK -15%	ACRS -59%
Cash On Hand	$663.6 Million	4/13	IQV $1.7B	NTRA $945.6M	MEDP $669.4M	QGEN $663.6M	ICLR $538.8M	GH $525.5M	NEO $367.0M	SHC $277.2M	NEOG $140.2M	OLK $109.3M	SYNH $82.2M	AKU $38.0M	ACRS $24.6M
Short Term Debt	$53.5 Million	4/13	IQV $1.1B	NTRA $90.5M	SYNH $68.3M	QGEN $53.5M	AKU $42.9M	ICLR $29.8M	GH $29.2M	NEO $6.8M	OLK $4.1M	NEOG $2.6M	MEDP -$0	ACRS -$0	SHC -$0
Long Term Debt	$1.3 Billion	5/13	ICLR $3.5B	SYNH $2.8B	SHC $2.3B	AKU $1.4B	QGEN $1.3B	GH $1.3B	NEOG $889.9M	NEO $602.0M	IQV $173.0M	MEDP $126.2M	NTRA $96.6M	OLK $22.1M	ACRS $0
PE	110.27	1/13	QGEN 110.27	SHC 81.85	SYNH 62.59	MEDP 21.72	IQV 18.00	ICLR 13.43	ACRS -1.00	NEO -1.00	NEOG -1.00	NTRA -1.00	GH -1.00	AKU -1.00	OLK -1.00
PS	4.66	5/13	OLK 18.91	NTRA 12.28	ACRS 7.06	GH 6.82	QGEN 4.66	MEDP 4.17	SHC 3.30	IQV 1.60	NEOG 1.57	ICLR 1.28	SYNH 0.82	NEO 0.31	AKU 0.04
PB	2.58	7/13	AKU 47.46	NTRA 17.43	MEDP 10.64	SHC 8.97	OLK 7.03	IQV 4.07	QGEN 2.58	SYNH 1.28	ICLR 1.12	ACRS 0.85	NEOG 0.54	NEO 0.22	GH 0.00
PC	13.89	6/13	SYNH 54.25	OLK 29.67	NTRA 22.03	ICLR 19.73	IQV 14.52	QGEN 13.89	MEDP 13.12	SHC 13.11	NEOG 10.23	GH 9.59	ACRS 5.38	AKU 0.70	NEO 0.55
Liabilities to Equity	0.59	7/13	SHC 6.59	IQV 3.43	MEDP 1.54	SYNH 1.31	NEO 0.82	ICLR 0.77	QGEN 0.59	NEOG 0.52	ACRS 0.42	NTRA 0.39	OLK 0.18	GH 0.00	AKU 0.00
ROA	0.01	4/13	MEDP 19%	IQV 5%	ICLR 5%	QGEN 1%	SYNH 1%	SHC 1%	NEO -5%	OLK -6%	NTRA -11%	NEOG -12%	AKU -14%	GH -29%	ACRS -60%
ROE	0.02	7/13	GH 312%	AKU 128%	MEDP 49%	IQV 23%	SHC 11%	ICLR 8%	QGEN 2%	SYNH 2%	OLK -7%	NEO -9%	NTRA -16%	NEOG -18%	ACRS -85%
Current Ratio	2.68	5/13	OLK 6.68	NTRA 3.57	ACRS 3.40	NEOG 2.93	QGEN 2.68	ICLR 2.29	NEO 2.23	SYNH 1.76	MEDP 1.65	IQV 1.29	SHC 1.15	AKU 1.00	GH 0.91
Quick Ratio	0.54	4/13	QGEN 110.27	SHC 81.85	SYNH 62.59	MEDP 21.72	IQV 18.00	ICLR 13.43	ACRS -1.00	NEO -1.00	NEOG -1.00	NTRA -1.00	GH -1.00	AKU -1.00	OLK -1.00
Long Term Debt to Equity	0.38	4/13	SHC} 5.75	SYNH} 0.81	NEO} 0.67	QGEN} 0.38	ICLR} 0.37	NEOG} 0.33	MEDP} 0.15	NTRA} 0.08	OLK} 0.05	IQV} 0.03	ACRS} 0.00	AKU} -8.04	GH} -9.36
Debt to Equity	0.39	4/13	SHC 5.81	SYNH 0.83	NEO 0.67	QGEN 0.39	ICLR 0.37	NEOG 0.33	IQV 0.22	NTRA 0.16	MEDP 0.15	OLK 0.06	ACRS 0.00	AKU -8.28	GH -9.57
Burn Rate	-30.97	13/13	NTRA 11.78	NEO 8.93	OLK 6.11	SHC 3.43	GH 3.08	SYNH 0.64	NEOG 0.28	ACRS 0.25	AKU 0.23	ICLR -4.85	MEDP -5.98	IQV -11.83	QGEN -30.97
Cash to Cap	0.07	8/13	NEO 1.82	AKU 1.44	ACRS 0.19	NEOG 0.10	GH 0.10	MEDP 0.08	SHC 0.08	QGEN 0.07	IQV 0.07	ICLR 0.05	NTRA 0.05	OLK 0.03	SYNH 0.02
CCR	1.62	1/13	QGEN 1.62	MEDP 1.56	ICLR 1.07	GH 0.75	OLK 0.52	ACRS 0.46	NEO 0.12	AKU -0.06	NEOG -0.17	NTRA -0.65	SHC -0.82	SYNH -65.12	IQV
EV to EBITDA	52.42	6/13	NEO} 119.47	MEDP} 65.74	SHC} 65.48	SYNH} 64.31	AKU} 58.89	QGEN} 52.42	ICLR} 37.35	IQV} 23.78	NEOG} -4.78	ACRS} -7.72	GH} -58.97	OLK} -151.26	NTRA} -436.04
EV to Revenue	5.03	6/13	OLK 18.43	NTRA 11.83	GH 7.91	ACRS 5.74	SHC 5.19	QGEN 5.03	MEDP 3.91	NEOG 2.39	AKU 1.98	ICLR 1.65	IQV 1.58	SYNH 1.34	NEO 0.67

Qiagen N.V. Peer Comparison

Cookies